

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SANDOZ INC.,
APOTEX INC., APOTEX CORP.,
EMCURE PHARMACEUTICALS LTD.,
HERITAGE PHARMA LABS INC.,
HERITAGE PHARMACEUTICALS INC.,
GLENMARK PHARMACEUTICALS, INC., USA,
GLENMARK HOLDING SA,
GLENMARK PHARMACEUTICALS, LTD.,
MYLAN LABORATORIES LIMITED,
TEVA PHARMACEUTICALS USA, INC.,
FRESENIUS KABI USA, LLC, and WOCKHARDT BIO AG,

Petitioners

v.

ELI LILLY AND COMPANY,

Patent Owner.

Case IPR2016-00318¹
U.S. Patent 7,772,209

PETITIONER'S UPDATED EXHIBIT LIST

¹ Cases IPR2016-01429, IPR2016-01393, and IPR2016-01340 have been joined with the instant proceeding.

Exhibit No.	Description	Filing Date
Exhibit 1001	U.S. Patent No. 7,772,209	12/14/2015
Exhibit 1002	File History of U.S. Patent Application No. 11/776,329, which issued as U.S. Patent No. 7,772,209 on August 10, 2010	12/14/2015
Exhibit 1003	Findings Of Fact And Conclusions Of Law Following Bench Trial August 19, 2013, in <i>Eli Lilly & Co. v. Teva Parenteral Medicines, Inc.</i> , Case No. 1:10-cv-1376, Dkt. 336 (S.D. Ind. March 31, 2014)	12/14/2015
Exhibit 1004	Declaration of Ron D. Schiff, M.D., Ph.D.	12/14/2015
Exhibit 1005	U.S. Patent No. 5,217,974	12/14/2015
Exhibit 1006	C. Niyikiza, <i>et al.</i> , <i>MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity</i> , <i>Annals Oncology</i> 9 (Suppl. 4): 125-140, Abstract 609P, (1998)	12/14/2015
Exhibit 1007	Hilary Calvert, <i>An Overview of Folate Metabolism: Features Relevant to the Action and Toxicities of Antifolate Anticancer Agents</i> , <i>Seminars Oncology</i> , 26: 3-10 (1999)	12/14/2015
Exhibit 1008	<i>Textbook of Small Animal Medicine</i> (John K. Dunn ed. 1999)	12/14/2015

Exhibit No.	Description	Filing Date
Exhibit 1009	Sidney Farber, <i>et al.</i> , <i>Temporary Remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin)</i> , <i>New Eng. J. Med.</i> , 238(23): 787-793 (Ex. 2042 in IPR2016-00237, -240) ²	12/14/2015
Exhibit 1010	Sarah L. Morgan, <i>et al.</i> , <i>Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis</i> , <i>Annals Internal Med.</i> , 121: 833-841 (1994)	12/14/2015
Exhibit 1011	G.B. Grindey, <i>et al.</i> , <i>Reversal of the toxicity but not the antitumor activity of Lometrexol by folic acid</i> , <i>Am. Ass'n Cancer Res.</i> , 32: 324, Abstract 1921 (1991)	12/14/2015
Exhibit 1012	Laurane G. Mendelsohn, <i>et al.</i> , <i>Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887</i> , in <i>Anticancer Drug Dev. Guide: Antifolate Drugs Cancer Therapy</i> , (Ann L. Jackman, ed.) Ch. 12: 261-80 (1999)	12/14/2015

² Pursuant to the parties' December 6, 2016 stipulation that the transcript of Dr. Steven Zeisel's deposition in IPR2016-00237 and -240 may be filed in the above-captioned proceeding, cross-references to the corresponding exhibit numbers in IPR2016-00237, and -240 are provided. (Paper 48, Stipulation Regarding the Deposition of Dr. Steven H. Zeisel, M.D., Ph.D.)

Exhibit No.	Description	Filing Date
Exhibit 1013	John F. Worzalla, <i>et al.</i> , <i>Role of Folic Acid in Modulating the Toxicity and Efficacy of the Multitargeted Antifolate, LY231514</i> , <i>Anticancer Res.</i> , 18: 3235-3240 (1998)	12/14/2015
Exhibit 1014	L. Hammond, <i>et al.</i> , <i>A Phase I and Pharmacokinetic (PK) Study of the Multitargeted Antifol (MTA) LY231514 with Folic Acid</i> , <i>Proc. Am. Soc’y Clinical Oncology</i> , 17: Abstract 866 (1998)	12/14/2015
Exhibit 1015	L. Hammond, <i>et al.</i> , <i>A phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA)</i> , <i>Annals Oncology</i> , 9: 129, Abstract 620P (1998)	12/14/2015
Exhibit 1016	C. Niyikiza, <i>et al.</i> , <i>LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity</i> , <i>Proc. Am. Ass’n Cancer Res.</i> , 17: 558a, Abstract 2139 (1998)	12/14/2015
Exhibit 1017	R. Thödtmann, <i>et al.</i> , <i>Preliminary Results of a Phase I Study with MTA (LY231415) in Combination with Cisplatin in Patients with Solid Tumors</i> , <i>Seminars Oncology</i> , 26 (2, Suppl. 6): 89-93 (1999)	12/14/2015
Exhibit 1018	U.S. Patent No. 5,563,126	12/14/2015
Exhibit 1019	Ernest Beutler & James K. Weick, <i>Blood and Neoplastic Disorders, in Current Clinical Practice</i> (Messerli, ed., 1987), Ch. 1: 291-302	12/14/2015
Exhibit 1020	Lars Brattström, <i>Vitamins as Homocysteine-Lowering Agents</i> , <i>J. Nutrition</i> , 126: 1276S-1280S (1996)	12/14/2015

Exhibit No.	Description	Filing Date
Exhibit 1021	Chuan Shih, <i>et al.</i> , <i>LY231514, a Pyrrolo[2,3-d]pyrimidine-based Antifolate That Inhibits Multiple Folate-requiring Enzymes</i> , <i>Cancer Res.</i> , 57, 1116-1123 (1997)	12/14/2015
Exhibit 1022	G. Robbin Westerhof, <i>et al.</i> , <i>Carrier- and Receptor-Mediated Transport of Folate Antagonists Targeting Folate-Dependent Enzymes: Correlates of Molecular-Structure and Biological Activity</i> , <i>Am. Soc'y Pharmacology Experimental Therapeutics</i> , 48: 459-471 (1995)	12/14/2015
Exhibit 1023	F. G. Arsenyan, <i>et al.</i> , <i>Influence of Methylcobalamin on the Antineoplastic Activity of Methotrexate</i> , <i>Pharmaceutical Chemistry J.</i> , 12(10): 1299-1303 (1978)	12/14/2015
Exhibit 1024	File History of U.S. Patent Application No. 11/288,807, Abandoned	12/14/2015
Exhibit 1025	U.S. Food & Drug Administration, <i>Approved Drug Products with Therapeutic Equivalents Evaluations</i> (30th ed. 2010)	12/14/2015
Exhibit 1026	Z.P. Sofyina, <i>et al.</i> , <i>Possibility to Increase the Antitumor Effect of Folic Acid Antagonist with the Help of Methylcobalamine Analogs</i> , <i>Sci. Center Oncology</i> 1:72-78 (1979)	12/14/2015
Exhibit 1027	Victor Herbert, <i>The Role of Vitamin B₁₂ and Folate in Carcinogenesis</i> , <i>Advances Experimental Med. Biology</i> , 206: 293-311 (1986)	12/14/2015
Exhibit 1028	Glenn Tisman, <i>et al.</i> , <i>Overcoming Colon Cancer Resistance to Hepatic Artery Infusional 5FUdR Chemotherapy with Folinic Acid</i> , <i>Clinical Res.</i> , 33(2): 459A (1985)	12/14/2015

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.